<?xml version="1.0" encoding="ISO-8859-1"?>
<brand>
	<title><![CDATA[TYVERB]]></title>
	<colour><![CDATA[#99cc33]]></colour>
	<logo>tyverb.png</logo>
	<rootVideo>brain_move_longer_1920.mov</rootVideo>
	<rootCaption>
		<copy><![CDATA[Despite progression, continuous blockade of HER2 signaling has been shown to be an effective strategy for prolonging response.]]></copy>
	</rootCaption>
	
	<menu contentID="0">
		<!-- LANDSCAPE AND PRODUCT OVERVIEW -->
		<item id="0" contentID="1"><![CDATA[LANDSCAPE AND PRODUCT OVERVIEW]]></item>
			
		<!-- TYVERB PLUS AROMATASE INHIBATOR -->
		<item id="1" contentID="2"><![CDATA[TYVERB PLUS AROMATASE INHIBATOR]]></item>

		<!-- TYVERB PLUS CAPECITABINE -->
		<item id="2" contentID="0"><![CDATA[TYVERB PLUS CAPECITABINE]]></item>
		
		<!-- TYVERB IN COMBINATION WITH TRASTUZUMAB -->
		<item id="3" contentID="0"><![CDATA[TYVERB IN COMBINATION WITH TRASTUZUMAB]]></item>
			<item id="3.0" contentID="1"><![CDATA[NOW APPROVED IN HER2+/HR- DISEASE]]></item>
			<item id="3.1" contentID="0"><![CDATA[STUDY DESIGN AND RESULTS]]></item>
			<item id="3.2" contentID="0"><![CDATA[MECHANISM OF ACTION]]></item>
			<item id="3.3" contentID="0"><![CDATA[SAFETY AND DOSING]]></item>

		<!-- SUMMARY OF PRODUCT CHARACTERISTICS -->
		<item id="4" contentID="0"><![CDATA[SUMMARY OF PRODUCT CHARACTERISTICS]]></item>

	</menu>
	
	<content>
		<content id="0" action="video-bg" videoID="tyverb-root" cuePointSet="tyverb-root" />
		<content id="1" action="slideshow-box" slideshowID="landscape-product-overview" />
		<content id="2" action="video-box" videoID="big_buck_bunny" />
	</content>
	
	<slideshows>
		<slideshow id="landscape-product-overview">
			<slide></slide>
			<slide></slide>
			<slide></slide>
			<slide></slide>
		</slideshow>
	</slideshows>
	
	<videos>
		<video id="tyverb-root" filename="brain_move_longer_1920.mov" loopInFrame="51" loopOutFrame="348" />
		<video id="big_buck_bunny" filename="big_buck_bunny.mp4" />
	</videos>
	
	<cuePointSets>
		<cuePointSet id="tyverb-root">
			<cuePoint id="cue1" inFrame="60" outFrame="187" boxXY="49,272" boxWidth="321">
				<title><![CDATA[PROVEN EFFICACY IN A RANGE OF PATIENTS]]></title>
				<body><![CDATA[TYVERB combination therapy has been proven effective in a range of patients with HER2+ mBC across lines of therapy]]></body>
				<footer><![CDATA[Cameron 2008/p535/C2/para 4/lines 6-8, p537/Figure 2/A, p 538/table 2; Johnston 2009/p5538/abstract/para 3/lines 1-3]]></footer>
			</cuePoint>
			<cuePoint id="cue2" inFrame="212" outFrame="344" boxXY="49,272" boxWidth="321">
				<title><![CDATA[HER2+ mBC]]></title>
				<body><![CDATA[Despite progression, continuous blockade of HER2 signaling has been shown to be an effective strategy for prolonging response]]></body>
				<footer><![CDATA[Wang 2011/p 17/col 2/para 2; Blackwell 2012/p2585/Abstract/Conclusion; Gori 2011/p 5/col 1/para 4; p 5/col 2/para 4]]></footer>
			</cuePoint>
		</cuePointSet>
	</cuePointSets>
</brand>